Table 2 SARS-CoV-2 IgG binding antibody responses IgG serum antibody titers to vaccine (S-2P-WA-1 and Omicron B.1.1.529 strains) and reported as areas under the curve (AUC) via a 10-plex ECLIA assay.

Primary EUA immunization

Vaccine

Janssen

Moderna

Pfizer/BioNTech

Ad26.COV2-S

mRNA-1273

BNT162b2

5 × 10¹⁰ vp

100-mcg

30-mcg

Booster

Day 1 GMT^a (95% CI)^b

4123.0

18,310.7

14,083.8

(2352.67–7225.51)

(11,647.69-28,785.21)

(9270.68-21,395.63)

N = 20

N = 16

N = 31

Day 15 GMT (95% CI)

22,969.7

50,130.9

44,295.7

(15,905.3–33,171.7)

(44,100.3–56,986.2)

(39,894.3–49,182.7)

N = 19

N = 15

N = 29

Day 29 GMT (95% CI)

20,950.5

46,053.9

42,857.8

(13,923.5–31,524.0)

(38,716.7–54,781.5)

(38,031.1–48,297.0)

N = 18

N = 14

N = 29

Day 91 GMT (95% CI)

15,093.62

44,220.6

38,321.0

(9651.7–23,603.8)

(35,889.0–54,486.3)

(30,415.6–48,281.0)

N = 19

N = 13

N = 25

Percentage with twofold rise at Day 15 (95% CI)

84.2%

60.0%

62.1%

(60.4–96.6%)

(32.3–83.7%)

(42.3–79.3%)

Geometric mean fold rise at Day 15 (95% CI)

5.2

2.8

3.2

(3.3–8.3)

(1.8–4.3)

(2.2–4.8)

Day 1 GMT (95% CI)

535.5

3511.1

3269.6

(277.0–1035.0)

(1750.2–7043.9)

(1828.8–5845.6)

N = 20

N = 16

N = 31

Day 15 GMT (95% CI)

(n)

5968.6

21,524.8

16,656.8

(3459.4–10,297.6)

(15,803.9–29,316.7)

(13,114.4–21,156.1)

N = 19

N = 15

N = 29

Day 29 GMT (95% CI)

(n)

5164.3

17,202.8

15,484.3

(2788.6-9564.0)

(1129.70–26,210.7)

(11,969.5–20,031.4)

N = 18

N = 14

N = 29

Day 91 GMT (95% CI)

(n)

3184.4

14,911.9

13,089.4

(1790.0-5665.1)

(8938.6–24,877.0)

(8831.1–19,401.0)

N = 19

N = 13

N = 25

GM fold decrease relative to WA-1 at Day 15 (95% CI)

4.7

3.0

2.9

(3.8–5.9)

(2.2–4.1)

(2.4–3.5)

Day 15 geometric mean fold rise (95% CI)

11.8

6.0

5.4

(6.6–21.1)

(3.1–11.4)

(3.3–8.7)